Cargando…

DNA methylation analysis improves the prognostication of acute myeloid leukemia

Integration of orthogonal data could provide new opportunities to pinpoint the underlying molecular mechanisms of hematologic disorders. Using a novel gene network approach, we integrated DNA methylation data from The Cancer Genome Atlas (n = 194 cases) with the corresponding gene expression profile...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samimi, Hanie, Mehta, Isha, Docking, Thomas Roderick, Zainulabadeen, Aamir, Karsan, Aly, Zare, Habil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Haematologic Malignancy ‐ Myeloid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294109/ https://www.ncbi.nlm.nih.gov/pubmed/34308417 http://dx.doi.org/10.1002/jha2.187

Ejemplares similares

Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada
por: Cressman, Sonya, et al.
Publicado: (2020)

“iNETgrate”: integrating DNA methylation and gene expression data in a single gene network
por: Sajedi, Sogand, et al.
Publicado: (2023)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
por: Patel, Shyam A., et al.
Publicado: (2023)

Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
por: Swaminathan, Mahesh, et al.
Publicado: (2022)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Molecular characteristics and outcomes in Hispanic and non‐Hispanic patients with acute myeloid leukemia
por: Bradley, Terrence, et al.
Publicado: (2022)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Prophylaxis with low dose tranexamic acid in acute myeloid leukemia patients undergoing intensive chemotherapy
por: Bønløkke, Søren Thorgaard, et al.
Publicado: (2023)

Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect(®) MDS/AML Disease Registry
por: Pollyea, Daniel A., et al.
Publicado: (2020)

De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China
por: Luo, Jie, et al.
Publicado: (2022)

Models of care for chronic myeloid leukemia patients during the COVID‐19 pandemic in the United Kingdom: Changes in patient attitudes to remote consultations and future implications
por: Duncan, Nicholas, et al.
Publicado: (2021)

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies
por: How, Joan, et al.
Publicado: (2022)

Increased body mass index is a risk factor for acute promyelocytic leukemia
por: Kashanian, Sarah M., et al.
Publicado: (2021)

The different predictive effects of the intensity and proportion of CD20 expression on the prognosis of B‐lineage acute lymphocyte leukemia
por: Tian, Yun, et al.
Publicado: (2022)

Acute leukemias in pregnant women: Results of a retrospective study at a local tertiary‐care hospital in Japan
por: Kobayashi, Shuhei, et al.
Publicado: (2023)

Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia
por: Cressman, Sonya, et al.
Publicado: (2016)

GSK3 inhibitor enhances gemtuzumab ozogamicin‐induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance
por: Inase, Aki, et al.
Publicado: (2022)

Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers
por: Hernlund, Emma, et al.
Publicado: (2021)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
por: Ishida, Hisashi, et al.
Publicado: (2020)

Single cell proteogenomic sequencing identifies a relapse‐fated AML subclone carrying FLT3‐ITD with CN‐LOH at chr13q
por: Kim, TaeHyung, et al.
Publicado: (2022)

Predictors of vascular disease in myelodysplastic syndromes
por: Faber, Mark G., et al.
Publicado: (2020)

Fatal renal diseases among patients with hematological malignancies: A population‐based study
por: Li, Sen, et al.
Publicado: (2020)

Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy
por: Galiègue‐Zouitina, Sylvie, et al.
Publicado: (2021)

PD1 expression on bone marrow T‐cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy
por: Bassiouny, Noha, et al.
Publicado: (2020)

Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK
por: Carpenter, Lewis, et al.
Publicado: (2022)

Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy
por: Symeonidou, Vasiliki, et al.
Publicado: (2022)

Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes
por: Rozema, Johanne, et al.
Publicado: (2022)

Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)
por: Bossi, Elisa, et al.
Publicado: (2022)

Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients
por: Wang, Yu‐Hung, et al.
Publicado: (2022)

Germline RUNX1 variants in paediatric patients in a French specialised centre
por: Liu, Cécile, et al.
Publicado: (2022)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
por: Ayala, Rosa, et al.
Publicado: (2023)

Incidence of blast phase in myelofibrosis according to anemia severity
por: Mora, Barbara, et al.
Publicado: (2023)

The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
por: Orbell, Lai Yee, et al.
Publicado: (2023)

A 4‐gene expression score associated with high levels of Wilms Tumor‐1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia
por: Niavarani, Ahmadreza, et al.
Publicado: (2016)

Acute myeloid leukaemia: challenges and real world data from India
por: Philip, Chepsy, et al.
Publicado: (2015)

Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome
por: Xu, Jinglan, et al.
Publicado: (2008)

Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications
por: Foroushani, Amir, et al.
Publicado: (2017)

Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd
por: Hughes, Timothy P., et al.
Publicado: (2017)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
por: Brümmendorf, Tim H., et al.
Publicado: (2015)

The value of molecular stratification for CEBPA (DM) and NPM1 (MUT) FLT3 (WT) genotypes in older patients with acute myeloid leukaemia
por: Dickson, Glenda J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hm78rg6ruj6515lgfudqtlvt9v